A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes

What Was Tested

The paper reports a study of Insulin Aspart and Insulin Lispro, published as a randomized controlled trial.

Who Took Part

The age groups tagged for this paper are young children, children and teenagers, both men and women.

Children and adolescents aged 4-18 years with diagnosed type 1 diabetes >or=1 year previously and treated with insulin analog in a CSII >or=3 months were randomly assigned 2:1 to 16 weeks of insulin aspart CSII (n = 198) or insulin lispro CSII (n = 100) in this open-label, parallel-group, multicenter study.

How the Study Was Run

The design is described as randomized, open-label, multicenter and parallel-group.

Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Insulin Aspart study did not mask who received what.

Running at several centres spread the Insulin Aspart study over different clinics and patient groups.

Groups ran in parallel: each of the participants stayed in one arm throughout.

What Was Measured

Topics PubMed links to this paper include Age Distribution, Blood Glucose, Body Mass Index, Diabetes Mellitus, Type 1, Glycated Hemoglobin, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Insulin Aspart and Insulin Lispro.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (Diabetes care), a journal based in United States.

More context: the Insulin Aspart compound page and the Insulin Lispro compound page.